Valeant Pharmaceuticals International
News and Blogs
Total : 1 View more »
Valeant to Acquire Polish Products (PR Newswire)
finance.yahoo.com
ALISO VIEJO, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX - News) today announced that it has agreed to acquire the rights to several
http://finance.yahoo.com/news/Valeant-to-Acquire-Polish-prnews-3666281567.html?x=0&.v=1
News from Zibb.com
Total : 20 View more »
Valeant Pharmaceuticals International Up 30% Since SmarTrend's Buy Recommendation - Zibb.com
Nov 12, 2009 (SmarTrend(R) Spotlight via COMTEX) --
SmarTrend, our proprietary pattern recognition system, called an Uptrend for Valeant Pharmaceuticals International (NYSE:VRX) on July 31, 2009 at $25.63.
Since then, Valeant Pharmaceuticals International has returned 30% as of today's recent price of $33.32. Want to profit from these alerts?
Go to www.mysmartrend.com now for a FREE two-week trial.
Write to Chip Brian at cbrian@tradethetrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html
Tags: market nyse pharmaceuticals profit securities trial
Companies: Valeant Pharmaceuticals International (VRX)
Valeant Pharmaceuticals International (VRX) Bullish Technical Alert - Trend Up 23.8% - Zibb.com
Nov 05, 2009 (SmarTrend(R) Spotlight via COMTEX) --
Valeant Pharmaceuticals International (NYSE:VRX) is trading 1.7% higher (up $0.54 to $31.72) today on volume of 254,822 shares. The stock is trading near its 52-week high of $32.00. We are watching for a close above that level.
Valeant Pharmaceuticals International is currently above its 50-day moving average of $27.97 and above its 200-day moving average of $23.02.
SmarTrend is bullish on shares of VRX and our subscribers received an Uptrend alert on July 31, 2009 at $25.63, which has returned 23.8% to date.
Write to Chip Brian at cbrian@tradethetrend.com
---------------------------------------------------------------------------------------------
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html
Tags: market nyse pharmaceuticals securities
Companies: Valeant Pharmaceuticals International (VRX)
Valeant Pharmaceuticals International (VRX) Corporate Event Announcement Notice - Zibb.com
Nov 02, 2009 (Wall Street Horizon via COMTEX) --
Valeant Pharmaceuticals International (VRX)
Expected next earnings release: Announcement date: 11/2/2009 - Before Market Earnings Quarter: Q3 Announcement Status: Verified
Expected next investor conference call information: Conference Call Date: 11/2/2009 Conference Call Time (ET): 10:00 AM Conference Call URL: http://phx.corporate-ir.net/phoenix.zhtml?c=119269&p=irol-presentations
Tags: conference corporate earnings market pharmaceuticals
Companies: Valeant Pharmaceuticals International (VRX)
Valeant Pharmaceuticals International declares income from continuing operations of USD37.6m for Q3
Nov 03, 2009 (M2 EQUITYBITES via COMTEX) --
Speciality pharmaceutical company Valeant Pharmaceuticals International (NYSE:VRX) reported on Monday income from continuing operations of USD37.6m (USD0.45 per diluted share) for the third quarter of 2009.
This is compared to a loss from continuing operations of USD7.3m (loss of USD0.08 per diluted share) for the third quarter of 2008. A Total revenue of USD220.3m was generated in the third quarter of 2009, a hike of 31% as compared to USD168.4m in the third quarter of 2008. A Research and development costs went down 51% to USD11.3m in the third quarter of 2009, from USD23.2m in the corresponding period in 2008, primarily due to the company's new leveraged R&D model.
Valeant has raised its cash EPS target to between USD2.10 and USD2.20 in 2009, up from the prior guidance of USD1.90 to USD2.10.
Comments on this story may be sent to admin@m2.com
Tags: eps nyse pharmaceuticals research and development revenue
Companies: Valeant Pharmaceuticals International (VRX)
Web Sites
Total : 16 View more »
Valeant Pharmaceuticals - Analyst News | newratings.com
Copyright © 2002 - 2008 newratings.com GmbH | Legal | Licensing Quote data provided by IS.eFinance Solutions (powered by IS.Teledata AG) using StandardPoor's ComStock Inc. and others. Delay times are 15 mins for European exchanges and NASDAQ, 20 mins for NYSE and AMEX.
http://www.newratings.com/headlines/Valeant-Pharmaceuticals_US91911X1046.html
VALEANT PHARMACEUTICALS INTERNATIONAL
it.zibb.com
Valeant Pharmaceuticals International® is a registered trademark used for Research and Development Services In the Field of Pharmaceuticals Except Clinical Research Services and owned by Valeant Pharmaceuticals International.
http://it.zibb.com/trademark/valeant+pharmaceuticals+international/30657537
Valeant Pharmaceuticals International - Company Profile - Computer Business Review
** NEW FEATURE ** Sign-up for NewsAlerts on Valeant Pharmaceuticals International so that whenever news breaks on this company you are amongst the first to know. Click here...
http://www.computerbusinessreview.com/companyprofile.asp?guid=AE7A5A36-D349-4A3C-8CD0-42575D261093
Professional Portfolio
Prior to joining Valeant, Mr. Cooper was Vice President of Global Operational Excellence for GlaxoSmithKline plc, where his leadership and executive experience included the management of global process-improvement projects and the identification, and sharing, of global best practices.
http://www.isssp.com/lc04.asp?page=professional_profile&show=100019888
Web Sites
powered by 
Total : 67,100 View more »
Valeant Pharmaceuticals International
www.valeant.com
Development and marketing of medications used in the fields of neurology, dermatology and infectious diseases. Includes corporate and production details. Headquarters in Aliso ...
Valeant Pharmaceuticals International - Wikipedia, the free ...
en.wikipedia.org
Valeant Pharmaceuticals International is a pharmaceutical company with activities spanning the drug discovery pipeline from target identification through clinical trials and ...
http://en.wikipedia.org/wiki/Valeant_Pharmaceuticals_International
EDGAR ONLINE - VALEANT PHARMACEUTICALS INTERNATIONAL - SEC FILINGS
www.edgar-online.com
Form (Filer) Received ( Period) 4: VALEANT PHARMACEUTICALS INTERNATIONAL (HEALTHCOR L P)
Valeant » About Valeant » Contact Us
www.valeant.com
Please note that Valeant Pharmaceuticals International does not accept unsolicited requests for funding. For any other questions that you may have, please use the form below.
News from Zibb.com
- Valeant Pharmaceuticals International Up 30% Since SmarTrend's Buy Recommendation - Zibb.com
- Valeant Pharmaceuticals International (VRX) Bullish Technical Alert - Trend Up 23.8% - Zibb.com
- Valeant Pharmaceuticals International (VRX) Corporate Event Announcement Notice - Zibb.com
- Valeant Pharmaceuticals International declares income from continuing operations of USD37.6m for Q3
Explore Related Topics
- Stocks & Stock Market
- Medical, Pharmaceuticals & Biotechnology
- Health & Healthcare in General
- Health
- Pharmaceutical Science